Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 887 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EPOCH II Clear all

Conditions: Stress Disorders, Post-Traumatic
Interventions: Balovaptan, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Phoenix, Arizona • Bellflower, California • Panorama City, California + 12 more

Conditions: Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions: Artemisia Annua Leaf, placebo; Dietary Supplement · Other
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: massage therapy, visit with a volunteer, period of quiet time, questionaire about pain; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions: Radiation, Imiquimod, Cyclophosphamide; Radiation · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Mantle Cell Lymphoma
Interventions: bortezomib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 69 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 48
States / cities: San Francisco, California • Bloomington, Illinois • Canton, Illinois + 26 more

Conditions: Post-operative Complications, Surgical Site Infection, Surgical Wound Infection
Interventions: Prevena™ Incision Management System (PIMS), Standard-of-care Dressing; Device
Lead sponsor: KCI USA, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma, Granulosa Cell Ovarian Cancer
Interventions: TRC102, CT scan, Lomotil, Prochlorperazine, Metoclopramide, 5-HT3 antagonist, Aprepitant, Biopsy; Drug · Diagnostic Test · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Esophageal Carcinoma
Interventions: Cisplatin, Irinotecan, External Beam Radiation Therapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia
Interventions: bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction; Biological · Genetic
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced Solid Tumors, Metastatic Solid Tumors
Interventions: Mogamulizumab (KW-0761); Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Musculoskeletal Complications
Interventions: levocarnitine, placebo, questionnaire administration; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Brain Cancer Metastatic, CMV Viremia
Interventions: Valganciclovir; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions: Best Practice, Comparator Program, Best Practice, Usual Care, Internet-Based Intervention, Massage Therapy, Survey Administration; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: HIV-1 Infection
Interventions: Vorinostat; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Spinal Cord Injury
Interventions: C-Brace II, Traditional Care KAFO intervention; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-melanoma Skin Cancer
Interventions: Solaraze and Vaniqa; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Pressure Ulcers
Interventions: P400 mattress; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: NSCLC Stage IV
Interventions: Pembrolizumab, Radiation, Chemotherapy; Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, Lymphoma, B-Cell
Interventions: Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq; Drug · Device
Lead sponsor: Jennifer Amengual; Other
Eligibility: 15 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Stanford, California • New York, New York

Conditions: Neurofibromatosis 1, Neurofibroma, Plexiform
Interventions: Pirfenidone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more

Conditions: Knee Osteoarthritis
Interventions: Diet, Exercise; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Recurrent Head and Neck Carcinoma
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma
Interventions: Doxycycline, Ipilimumab, Temozolomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)

Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth

Massage Therapy in Treating Patients With Cancer Pain

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms

Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Evaluating a Mobile Health Application Intervention for Caregiver Instruction in Manual Therapy for Chemotherapy-Induced Peripheral Neuropathy

The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART

C-Brace II Spinal Cord Injury

Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer

P400 for Stage II-IV Pressure Ulcers in Home and Extended Care

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program

Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer

Doxycycline, Temozolomide and Ipilimumab in Melanoma